Favezelimab

Generic Name: Favezelimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2231068-83-8

Unique Ingredient Identifier: H1396W7D1H

Background: Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed ...

Merck announced that the Phase 3 KEYFORM-007 trial evaluating the combination of favezelimab and pembrolizumab did not meet its primary endpoint of overall survival for previously treated PD-L1 positive MSS mCRC patients. The safety profile was consistent with previous studies, with no new safety signals observed. A full data evaluation is ongoing, and Merck will share results with the scientific community.

Related Clinical Trials:

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy